Intra-Cellular Therapies (NASDAQ:ITCI) Stock Quotes, Forecast and News Summary

Q: What sector and industry does Intra-Cellular Therapies (ITCI) operate in?

Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Intra-Cellular Therapies Stock (NASDAQ: ITCI) stock price, news, charts, stock research, profile.

Open	$127.00
Close	-
Volume / Avg.	5.01M / 1.86M
Day Range	$127.00 - $127.60
52 Wk Range	62.78 - 128.00
Market Cap	$13.49B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	86
Short Interest	2.14%
Days to Cover	3.71

Recent News

Johnson & Johnson Q4 Earnings: Cancer Drugs Performance Drives Revenue Beat, Issues Strong FY25 Outlook

Johnson & Johnson's Q4 sales hit $22.52 billion, with strong growth in MedTech and oncology. 2025 guidance shows promising EPS and revenue forecasts.

Vandana Singh

Top 4 Health Care Stocks You May Want To Dump In Q1

Avi Kapoor

MicroStrategy, SoFi Technologies And Carvana Are Among Top Large-Cap Gainers Last Week (Jan 13-Jan 17): Are The Others In Your Portfolio?

These 11 large-cap stocks saw significant growth last week, with notable news from companies such as Johnson & Johnson, MicroStrategy, and United Rentals.

Lekha Gupta

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Aug 24

Sep 24

Oct 24

Nov 24

Jan

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.7

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$127.00
Close	-
Volume / Avg.	5.01M / 1.86M
Day Range	$127.00 - $127.60
52 Wk Range	62.78 - 128.00
Market Cap	$13.49B
P/E Ratio	-
Dividend Yield	-
Exchange	NASDAQ
RSI	86
Short Interest	2.14%
Days to Cover	3.71

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy Intra-Cellular Therapies (ITCI) stock?

You can purchase shares of Intra-Cellular Therapies (NASDAQ:ITCI) through any online brokerage.

View our list of the best stock brokerages

Who are Intra-Cellular Therapies (ITCI) competitors?

Other companies in Intra-Cellular Therapies’s space includes: Novo Nordisk (NYSE:NVO), Johnson & Johnson (NYSE:JNJ), Verona Pharma (NASDAQ:VRNA), Merck & Co (NYSE:MRK) and Novartis (NYSE:NVS).

What is the forecast, or price target, for Intra-Cellular Therapies (ITCI) stock?

Intra-Cellular Therapies has a consensus price target of $98.25.

What is the current price for Intra-Cellular Therapies (ITCI)?

The stock price for Intra-Cellular Therapies (NASDAQ: ITCI) is $127 last updated January 22, 2025 at 9:30 AM EST.

Does Intra-Cellular Therapies (ITCI) pay a dividend?

There are no upcoming dividends for Intra-Cellular Therapies.

When is Intra-Cellular Therapies (NASDAQ:ITCI) reporting earnings?

Intra-Cellular Therapies’s Q4 earnings are confirmed for Thursday, February 20, 2025.

Is Intra-Cellular Therapies (ITCI) going to split?

There is no upcoming split for Intra-Cellular Therapies.

What sector and industry does Intra-Cellular Therapies (ITCI) operate in?

Intra-Cellular Therapies is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.

Comments

Intra-Cellular Therapies

Intra-Cellular Therapies (ITCI) Forecast